

Nanoethics and Nanotoxicology

P. Houdy M. Lahmani F. Marano
(Eds.)

Nanoethics and Nanotoxicology

With 112 Figures and 31 Tables



EUROPEAN MATERIALS
RESEARCH SOCIETY



Philippe Houdy, PhD

Université d'Évry
Boulevard François Mitterrand, 91025 Évry Cédex, France
E-mail: philippe.houdy@univ-evry.fr

Marcel Lahmani, PhD

Club Nano-Micro-Technologie de Paris
Boulevard François Mitterrand, 91025 Évry Cédex, France
E-mail: marcel.lahmani@univ-evry.fr

Francelyne Marano

Université Paris Diderot-Paris 7, Laboratoire des RMCX
Bâtiment Buffon
rue Marie-Andrée Lagroua Weill-Hall 4, 75205 Paris Cédex, France

Translation from the French language edition of
“Les Nanosciences – 4. Nanotoxicologie et nanoéthique”
© 2010 Editions Belin, France

ISBN 978-3-642-20176-9

e-ISBN 978-3-642-20177-6

DOI 10.1007/978-3-642-20177-6

Springer Heidelberg Dordrecht London New York

Library of Congress Control Number: 2011935632

© Springer-Verlag Berlin Heidelberg 2011

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law.

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Cover design: WMXDesign GmbH, Heidelberg

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

*All is poison, nothing is poison,
only the dose matters*

Paracelsus (1493–1541)
Swiss alchemist and physician

Foreword to the French Edition

Science moves forward inexorably, and the ever more powerful means of investigation at its disposal provide a continuous supply of new discoveries and novel applications. The same is also true in the nanosciences. History has shown that scientific progress can lead to worldwide benefits, but sometimes also to unprecedented human disasters. This observation is not restricted to the products of the nanotechnologies, but the development here may be taken as an opportunity for a documented raising of awareness regarding their risks, consulting the general public on broad scale, and above all, informing the whole of society as objectively as possible.

Indeed, the very real problems raised by asbestos and the questions posed by the unknown long term impacts of genetically modified organisms (GMO) – more and more common in our everyday food supply – have caused considerable discord between the scientists who develop them, the companies who wish to industrialise them, and the consumer organisations. This kind of controversy is broadly covered by the media, with a view either to warn the public on behalf of competent and responsible organisations, or to achieve more or less dubious political ends.

The real problem here is to carry out a rigorous investigation of the potential dangers and risks raised by the use, development, and commercialisation of current or new products likely to threaten people's health or the environment, with harmful consequences for future generations. There is no doubt that the specific properties of nanoscale objects can radically enhance their chemical reactivity, and transform their electronic or magnetic behaviour, sometimes increasing their capacity to enter deep into living systems.

This book is the last of four volumes providing as complete a picture as possible of the current state of our knowledge in the nanosciences. The vocation of the series is didactic, aimed at graduate students, research scientists, and engineers. From a scientific standpoint, it reviews the state of the art in nanobiotechnology and nanotoxicology. But what is novel in this fourth volume is that it emphasises the efforts made by researchers to cater for the

VIII Foreword to the French Edition

consequences of their work, and the ways engineers set up safety systems when potentially dangerous products go into mass production.

To my knowledge, this is the first book in which scientific knowledge and ethical and social recommendations can be found side by side, along with specific policies developed by national and international authorities to handle the potential problems of nanotechnology.

President of the French National Ethical Committee
Hôpital Armand-Trousseau, Paris
University Pierre and Marie Curie, Paris

Alain Grimfeld
August 2007

Preface to the French Edition

Nanotoxicology studies the toxicity of nanomaterials, nanoparticles, and more generally, any naturally occurring or man-made objects with dimensions in the range 1–100 nanometers. Such small dimensions induce specific properties, making these objects much more reactive, for example, than larger ones, and in particular, they allow them to pass through certain natural biological barriers. The potentially harmful effects that may result thus constitute one of the quite legitimate reasons for the concern they inspire.

A key objective of this book is to set out some up-to-date scientific studies of nanotoxicity, and exemplify the preventive measures taken during fabrication or manipulation of nano-objects. Another is to describe the way the public is informed about these new scientific discoveries, and also the legal arrangements currently under preparation for regulating their use.

Considering the controversy to which the nanosciences have given rise – as witnessed for all forms of scientific innovation – it seems important to expose the ethical considerations taken into account in the context of nanotechnology. Indeed, scientists have been questioned, sometimes forcefully, about the social consequences of their research, and it seems opportune to set up a responsible debate between the so-called hard sciences and the social sciences from the very beginning of any scientific project with wide-ranging industrial and social impacts. Such attempts to raise public awareness are of course relevant both on the national and international level.

The book is divided into five main parts. The first two concern nanotoxicology, and are purely scientific, providing specific examples of the potential or proven impacts of nanoparticles on humans and on the environment. The last three concern nanoethics. After a brief introduction to the basic ethical issues, there is a fairly exhaustive discussion of the implications for national and international authorities regarding the way the public demand for information is being treated, and also regarding the degree of transparency with which current developments in nanotechnology are being presented, as well as the need for rigour, responsibility, and caution in their use.

The reader will thus find one of the first books to combine both scientific and societal aspects of an emerging field, containing many references for each of its disciplines.

Acknowledgements

We would like to thank all members of the French nanoscience community who gave a very favourable welcome to the writing of these four pedagogical introductions to nanotechnology and nanophysics, nanomaterials and nanochemistry, nanobiotechnology and nanobiology, and nanotoxicology and nanoethics, without whom they would have been impossible. Special thanks go, of course, to all those who contributed to these books.

Given the current debate over the nanosciences, it seemed important to mention in the context of a scientific textbook that research scientists do indeed take into account the potential risks involved in their innovations, and give considerable thought to all the necessary precautions before they are industrialised.

From the ethical standpoint, it is more and more important to inform the general public, and the book discusses the various authorities concerned with the citizen's demand for information when new technologies with suggested or proven risks are launched on the market. This part of the book was put together by Françoise Roure, president of the information technology department of the French Ministry for Trade and Industry. Her contribution played a key role in harmonising with the prior scientific chapters.

The latter were coordinated by Francelyne Marano, co-editor of the book, for the first part and by Jean-Yves Bottero for the second. We would like to express our most sincere gratitude for his scientific actions and for organising the working groups at the CEREGE.

We are particularly grateful to the late Professor Hubert Curien, who supported this undertaking from the start, and to Jean-Marie Lehn, Axel Kahn, and Alain Grimfeld, who have also given it their backing.

We warmly acknowledge the material and financial support of the French Ministry of Research, the French national science research organisation (CNRS), and the French atomic energy authority (CEA), and especially Jean Therme, Director of the CEA, Grenoble, who supported this project from the beginning.

The editors of the nanobooks would like to express their gratitude to Stephen N. Lyle for his excellent translation of the four nanovolumes of this Nanoscience series: *Nanotechnologies and Nanophysics*, *Nanomaterials and Nanochemistry*, *Nanobiotechnology and Nanobiology*, and *Nanotoxicology and Nanoethics*.

Marcel Lahmani
Francelyne Marano
Philippe Houdy

Contents

Introduction. Nanomaterials and Nanoproducts:	
World Markets and Human and Environmental Impacts . . .	XXXIII
<i>Eric Gaffet</i>	XXXIII
1 Nanotechnologies	XXXIV
2 Nanomaterials	XXXIV
3 Social and Economic Aspects	XXXV
3.1 Nanotechnology and Nanomaterials Markets	XXXV
3.2 Financing in France	XXXV
3.3 Production and Applications of Nanomaterials	XXXVI
3.4 Nanomaterials and Safety	XLI
4 The Need for Studies in Nanotoxicity and Nanoethics	XLII
References	XLII

Part I Nanotoxicity: Experimental Toxicology of Nanoparticles and Their Impact on Humans

1 Toxicity of Particles: A Brief History	3
<i>Marie-Claude Jaurand and Jean-Claude Pairon</i>	3
1.1 Sociological and Technical Factors Conditioning the Study of Particle Toxicity	4
1.2 Pathologies Caused by Inorganic Dusts	6
1.2.1 Pneumoconiosis	6
1.2.2 Cancer	7
1.3 Particles Causing Pathogenic Effects in the Airways and Respiratory System	8
1.3.1 Origin of Particles	8
1.3.2 Types of Particle	9
1.4 Evolution in the Methods for Investigating Toxicity	11
1.4.1 Studies on Animals	11
1.4.2 Isolated Cells	13
1.4.3 Molecular Epidemiology	14

1.5	Results on Particle Toxicity Mechanisms	15
1.5.1	Proven Major Risk Factors: Silica and Asbestos	15
1.5.2	Suspected Risk Factors: Artificial Mineral Fibres	20
1.5.3	Unknown Risk Factors: Nanoparticles	21
1.6	Results and Further Questions	22
1.7	Conclusions and Prospects	25
	References	26
2	Exposure, Uptake, and Barriers	37
	<i>Armelle Baeza-Squiban and Sophie Lanone</i>	37
2.1	Exposure	37
2.1.1	Which Environmental Compartment?	38
2.1.2	What Kind of Particles?	38
2.1.3	Exposure Context	39
2.1.4	Dose	39
2.2	Uptake	39
2.2.1	Respiratory Route	39
2.2.2	Cutaneous Route	44
2.2.3	Digestive Route	46
2.3	Barrier Crossing	47
2.3.1	Internalisation Mechanisms	47
2.3.2	Particle Translocation	51
2.4	Nanoparticle Biodistribution in the Organism. Elimination	55
2.5	Conclusion	57
	References	58
3	Experimental Models in Nanotoxicology	63
	<i>Armelle Baeza-Squiban, Ghislaine Lacroix, and Frédéric Y. Bois</i>	63
3.1	In Vivo Models	63
3.1.1	Different Animal Species Used	63
3.1.2	Types of Animal Model	64
3.1.3	Types of Exposure	66
3.1.4	Targets	68
3.2	In Vitro Models	69
3.2.1	Cell Cultures	70
3.2.2	In Vitro Methods in Regulatory Toxicology	71
3.2.3	In Vitro Methods for Assessing Nanoparticle Toxicity	71
3.2.4	Specific Problems for Assessing in Vitro Toxicity of Nanoparticles	74
3.3	Predicting Penetration and Fate of Nanoparticles in the Body	75
3.3.1	Pharmacokinetics	76
3.3.2	Pharmacokinetic Models	77
3.3.3	Examples of Applications to Nanomaterials	80
3.4	Conclusion	82
	References	83

4 Nanoparticle Toxicity Mechanisms:

Oxidative Stress and Inflammation	87
<i>Béatrice L'Azou and Francelyne Marano</i>	87
4.1 Introduction	87
4.1.1 From Particulate Toxicology to Nanotoxicology	87
4.1.2 Nanoparticles, Oxidative Stress, and Inflammation	88
4.1.3 Acute Inflammatory Reaction and Inflammatory Defence Against Chronic Pathologies	89
4.2 Interactions Between Nanoparticles and Biological Media, Including Proteins	90
4.3 Nanoparticles and Oxidative Stress	93
4.3.1 Reactive Oxygen Species (ROS)	93
4.3.2 Reactive Oxygen Species and Their Effects	95
4.3.3 Nanoparticles, ROS production, and Oxidative Stress	97
4.4 Nanoparticles and Inflammatory Response	99
4.4.1 Fine and Ultrafine Atmospheric Particles, Man-Made Nanoparticles, and Inflammation: A Clearly Established Relationship	99
4.4.2 Comparability of Cellular and Molecular Toxicity Mechanisms for Fine and Ultrafine Atmospheric Particles and Nanoparticles	102
4.5 Conclusion	104
References	105

5 Nanoparticle Toxicity Mechanisms: Genotoxicity

<i>Alain Botta and Laïla Benameur</i>	111
5.1 Mechanisms for Radical Species Production	111
5.1.1 Intrinsic Production	111
5.1.2 Production by Interaction with Cell Targets	112
5.1.3 Production Mediated by Inflammatory Reaction	112
5.2 General Genotoxicity Mechanisms	112
5.2.1 Direct Clastogenic Mechanisms	113
5.2.2 Indirect Clastogenic Mechanism	113
5.2.3 Aneugenic Mechanism	114
5.2.4 Production of DNA Adducts	114
5.3 Detection and Characterisation of Genotoxicity	115
5.3.1 Detecting Primary DNA Alterations	115
5.3.2 Detecting Gene Mutations	116
5.3.3 Detecting Chromosome Mutations	117
5.4 Nanoparticle Genotoxic Action Mechanisms: Current Data from the Main Scientific Studies	118
5.4.1 Carbon-Containing Nanoparticles	119
5.4.2 Metal-Containing Nanoparticles	123
5.4.3 Quantum Dots	128
5.4.4 Other Types of Nanoparticle	128

5.4.5	Comparative Studies Between Different Nanoparticles	130
5.4.6	Review of Genotoxicity Mechanisms	130
5.5	Conclusion	130
	References	142
6	Elements of Epidemiology	147
	<i>Agnès Lefranc and Sophie Larrieu</i>	<i>147</i>
6.1	Generalities	147
6.2	Studies of Ultrafine Particles and Lack of Data for Nanoparticles	148
6.3	Review of Epidemiological Studies of Ultrafine Particles Suspended in the Surrounding Atmosphere	149
6.3.1	Assessing Exposure	152
6.3.2	Health Indicators	153
6.3.3	Different Types of Analyses Carried out	154
6.3.4	Results	155
6.3.5	Interpretation of Findings	157
6.4	Drawing Conclusions about Intrinsic Nanoparticle Effects	159
	References	160
7	Monitoring Nanoaerosols and Occupational Exposure	163
	<i>Olivier Witschger</i>	<i>163</i>
7.1	Terminology and Definitions	164
7.1.1	Nanoparticles	164
7.1.2	Nanomaterials	166
7.2	Characterising Occupational Exposure	167
7.2.1	Conventional Approach to Aerosols	168
7.2.2	Measurement Criteria for Exposure to Nanoaerosols	170
7.2.3	Instrumentation and Methods	174
7.2.4	Sampling and Deposition of Particles	178
7.2.5	Sampling and Physicochemical Analysis	179
7.2.6	Measurement Strategies and Interpretation of Results	180
7.3	Occupational Exposure	183
7.3.1	Exposure Factors and Scenarios: Qualitative Aspects	183
7.3.2	Practical Approach to Identify the Nanoparticulate Character of a Work Context	187
7.3.3	Emission of Nanoparticles by Powdered Materials. Nanopowders	189
7.4	Setting Up Reference Concentrations	191
7.5	Conclusion and Prospects	193
	References	194
8	Monitoring Nanoaerosols and Environmental Exposure	201
	<i>Corinne Mandin, Olivier Le Bihan, and Olivier Aguerre-Chariol</i>	<i>201</i>
8.1	Origin and Nature of Environmental Exposure	202
8.1.1	Life Cycle and Environmental Exposure	202
8.1.2	Exposure Routes	202

8.2	Characterising Environmental Exposure	203
8.2.1	Nanoparticle Measurement in Air	204
8.2.2	Nanoparticle Measurement in Water	207
8.2.3	Nanoparticle Measurement in Soil	208
8.3	Conclusion	208
	References	208
9 Nanoparticles and Nanomaterials:		
Assessing the Risk to Human Health		
	<i>Denis Bard</i>	211
9.1	Identifying the Hazards	212
9.2	Dose–Response Relationship	215
9.3	Exposure	216
9.4	Conclusion	217
	References	217
10 Technical Risk Prevention in the Workplace		
	<i>Myriam Ricaud</i>	219
10.1	Prevention	220
10.2	Changing the Process	223
10.3	Collective Safety Measures	224
10.3.1	Closed Systems	224
10.3.2	Ventilating and Purifying the Workplace Atmosphere	225
10.3.3	Air Filtering in the Workplace	228
10.4	Organisational Measures	231
10.4.1	Work Area	231
10.4.2	Personal Hygiene	232
10.4.3	Product Storage	232
10.4.4	Waste Processing	233
10.4.5	Accident and Incident Management	233
10.5	Personal Safety	233
10.5.1	Respiratory Protection	233
10.5.2	Skin Protection	236
10.6	Informing Staff	237
10.6.1	Labelling	237
10.6.2	Safety Data Sheets	237
10.7	Staff Training	237
10.8	Conclusion	238
	References	239
11 Occupational Exposure to Nanoparticles and Medical Safety		
	<i>Patrick Brochard, Daniel Bloch, and Jean-Claude Pairon</i>	243
11.1	Should We Organise a Specific Occupational Safety Programme for Workers Coming into Contact with Nanoparticles?	244

11.2	What Should Be the Basis for Organising Specific Medical Monitoring?	245
11.2.1	What Experimental Toxicological Data Should Be Considered?	245
11.2.2	What Human Data Should Be Considered?	246
11.3	Implementing Medical Surveillance	252
11.3.1	Available Biomarkers	252
11.4	Publications on Medical Surveillance	255
11.5	What Is on Offer in France?	256
11.5.1	Surveillance Protocols for Cross-Sectional and Cohort Epidemiological Studies	256
11.5.2	Surveillance Protocols for Clinical Research Studies Screening the Effects of Controlled Exposure in the Laboratory	257
11.5.3	Surveillance Protocols in the Workplace	257
11.6	Conclusion	259
	References	260

Part II Nanotoxicity: Experimental Toxicology of Nanoparticles and Their Impact on the Environment

12	Surface Reactivity of Manufactured Nanoparticles	269
	<i>Mélanie Auffan, Jérôme Rose, Corinne Chanéac, Jean-Pierre Jolivet, Armand Masion, Mark R. Wiesner, and Jean-Yves Bottero</i>	269
12.1	Nanoscale Description of Surfaces	270
12.1.1	Surface Atoms	270
12.1.2	Excess Surface Energy	272
12.1.3	Surface Properties	274
12.2	Relation Between Surface Energy and Control of Size and Shape	275
12.2.1	Proton Adsorption–Desorption	275
12.2.2	Polyol Adsorption	276
12.3	Surface Reactivity and Photocatalysis	277
12.3.1	Photocatalysis: Definition	278
12.3.2	Effect of Particle Size on Photocatalysis	279
12.3.3	Environmental Applications of Photocatalysis	281
12.4	Surface Reactivity and Adsorption–Desorption	282
12.4.1	Pollutant Adsorption. Arsenic	282
12.4.2	Catalysis. MoS ₂ Particles	283
12.4.3	Dissolution and Salting out of Toxic Ions	284
12.5	Conclusion	285
	References	285

13 Fate of Nanoparticles in Aqueous Media	291
<i>Jérôme Labille and Jean-Yves Bottero</i>	291
13.1 Specific Features of Nanoparticles	293
13.1.1 Increased Specific Surface Area.....	293
13.1.2 Size-Related Surface Energy	293
13.1.3 Consequences for the Fate of Nanoparticles in the Environment	294
13.2 Nanoparticle Dispersion and Transport in Aqueous Media	295
13.2.1 Nanoparticle Surface Properties and Affinity for Water	295
13.2.2 Stability of Nanoparticles in Suspension. Dispersion and Aggregation	298
13.2.3 Nanoparticle Mobility and Attachment in Water-Saturated Porous Media	312
13.3 Conclusion	321
References	322
14 Ecotoxicology: Nanoparticle Reactivity and Living Organisms	325
<i>Mélanie Auffan, Emmanuel Flahaut, Antoine Thill, Florence Mouchet, Marie Carrière, Laury Gauthier, Wafa Achouak, Jérôme Rose, Mark R. Wiesner, and Jean-Yves Bottero</i>	325
14.1 Physicochemical Properties and Ecotoxicity of Nanoparticles	326
14.1.1 Nanoparticle Aggregation	327
14.1.2 Chemical Stability of Nanoparticles	329
14.1.3 Functionalised or Passivated Nanoparticles	330
14.2 Ecotoxicity for Bacteria.....	331
14.2.1 Bacteria.....	332
14.2.2 Effects of Nanoparticles on Bacterial Viability	333
14.2.3 Exposure of Bacteria to Nanoparticles	333
14.2.4 Oxidative Stress.....	337
14.3 Ecotoxicity for Aquatic Organisms	338
14.3.1 Carbon Nanoparticles	338
14.3.2 Metal and Metal Oxide Nanoparticles	346
14.3.3 Latex Nanoparticles	347
14.3.4 Co-contamination by Nanoparticles and Metals or Organic Pollutants	347
14.4 Phytotoxicity and Translocation in Plants.....	348
14.4.1 Basic Tools for Studying Nanoparticle Phytotoxicity	349
14.4.2 Phytotoxic Effects: Inhibition of Germination and Growth	349
14.4.3 Nanoparticle Translocation from Roots to Aerial Parts	350
14.5 Conclusion	350
References	352

15 Toxicological Models Part A: Toxicological Studies of Nanoparticles on Biological Targets and Attempts to Attenuate Toxicity by Encapsulation Techniques	359
<i>Roberta Brayner and Fernand Fiévet</i>	359
15.1 Chemical Synthesis of Nanoparticles and Toxicological Studies	363
15.1.1 Type II–VI Semiconductor Nanoparticles	364
15.1.2 ZnO Nanoparticles	367
15.2 New Ways to Synthesise Protected Nanoparticles with Reduced Toxicological Effects	370
15.2.1 Surface Functionalisation and Passivation of Type II–VI Semiconductor Nanoparticles	370
15.2.2 Nanoparticle Encapsulation by an SiO ₂ Shell	372
15.3 Conclusion	375
References	375
16 Toxicological Models Part B: Environmental Models	379
<i>Jeanne Garric and Eric Thybaud</i>	379
16.1 Types of Nanoparticles Investigated	380
16.2 Types of Preparation	380
16.3 Compartments	382
16.3.1 Terrestrial Compartment	382
16.3.2 Aquatic Compartment	385
16.4 Limitations of these Tests	391
16.5 Conclusion and Prospects	391
References	392
17 Life Cycle Models and Risk Assessment	397
<i>Jérôme Labille, Christine O. Hendren, Armand Masion, and Mark R. Wiesner</i>	397
17.1 Potential and Risks of Nanotechnologies	397
17.1.1 Hazards	399
17.1.2 Exposure	399
17.2 Monitoring Nanomaterials Throughout Their Life Cycle to Predict Emissions into the Environment	400
17.3 Nanomaterial Interactions with the Environment	402
17.3.1 Models for Estimating Existing Risks	403
17.3.2 The Situation for Nanomaterials	403
17.3.3 Degradation of Nanomaterials	404
17.3.4 Compiling Data	405
17.4 Characterising the Hazards of Nanotechnologies: Toxicity	405
17.5 Present State of Knowledge Regarding Nano Risk	406
17.6 Titanium Dioxide Nanoparticles in Sunscreen Creams	408
17.6.1 Protocol for Laboratory Reconstitution of Deterioration ...	409
17.6.2 Nanomaterial Dispersion Kinetics in an Aqueous Medium	410

17.6.3	Characterising Deterioration Reactions	411
17.6.4	Life Cycle in a Biotic Medium and Introduction into the Food Chain	412
17.7	Conclusion	415
	References	416

Part III Nanoethics: Ethical Questions Raised by Nanotechnology and Scientific Discovery on the Nanoscale

18 Nanoethics: Challenges and Opportunities	423
<i>Alain Pompidou</i>	423
References	426
19 Ethics and Medicine: Philosophical Guidelines for a Responsible Use of Nanotechnology	427
<i>Corine Pelluchon</i>	427
19.1 Definition of Ethics	427
19.2 Exacerbation of Problems Inherent in Conventional Techniques . . .	428
19.3 The Use of Nanotechnologies and Society's Purpose	429
19.4 What Criterion Can Distinguish Between Legitimate and Illegitimate Uses of Bionanotechnologies?	430
19.5 International Norms and the Political Community	432
References	433

Part IV Nanoethics and Regulation: The Situation in France

20 Situation in France: Ethical Reflection on Research in Nanoscience and Nanotechnology	437
<i>Jacques Bordé</i>	437
20.1 Awareness of Nanotechnological Risk in North America	437
20.2 Reaction of the European Union	437
20.3 Mobilisation of Research in the Human Sciences	438
20.4 Motivation for the Ethics Committee of the CNRS	439
20.5 A State of Turmoil in France	440
20.6 Position of the CNRS	441
20.7 The Position of Other French Institutions	443
20.8 Further Developments Within the CNRS	444
20.9 Recommendations by COMETS	445
20.10 Impact of the COMETS Conclusions and the Role of the CNRS in the Debate	446
20.11 Dialogue with Civil Society	447
20.12 Preparing Researchers for a New Form of Communication	448
20.13 Conclusion	449
References	451

21 Situation in France: Nanoparticles in the Grenelle Environment Forum	455
<i>Philippe Hubert</i>	455
21.1 Health–Environment Working Group and Conclusions of the Round Tables	455
21.2 Recommendations of the Three Operational Committees	457
21.3 Law and Prospects Opened by the Grenelle Environment Forum	459
21.4 Conclusion	459
22 Situation in France: The Position of a Federation of Environmental Protection NGOs	463
<i>José Cambou and Dominique Proy</i>	463
23 Situation in France: The Position of a Consumer Protection Group	475
<i>Christian Huard and Bernard Umbrecht</i>	475
23.1 French National Consumer Council	475
23.2 Consumer Information: Failings and Modest Steps Forward	477
23.3 The Need to Go Beyond Labels. A New Form of Governance	480
24 Situation in France: The Principle of Precaution	483
<i>François Ewald</i>	483
24.1 Definition	483
24.2 Legal Status of the Precautionary Principle	487
24.3 Decisional Aspects of the Precautionary Principle	488
24.3.1 Risk Assessment	489
24.3.2 Risk Management	489
24.3.3 Communication	490
24.4 Beyond the Principle of Precaution	490

Part V Nanoethics and Regulation: The Situation in Europe and the World

25 Situation in Europe and the World: A Code of Conduct for Responsible European Research in Nanoscience and Nanotechnology	497
<i>Philippe Galiay</i>	497
25.1 Introduction	497
25.2 European Research	498
25.3 EC Research and Nanotechnology	499
25.3.1 EC Strategy and Action Plan for Nanoscience and Nanotechnology	500

25.3.2	Support for Research in Nanoscience and Nanotechnology	500
25.4	Science in Society	501
25.4.1	Toward a Governance That Makes More Allowance for Scientific Knowledge	502
25.4.2	Elaboration, Dissemination, and Application of Ethical Rules	502
25.5	EC Recommendation for a Code of Conduct	503
25.5.1	Choice of Recommendation	503
25.5.2	Content of Recommendation	503
25.5.3	The Code of Conduct	504
25.5.4	Code of Conduct and Ethical Review	506
25.5.5	Code of Conduct and Regulation	507
25.5.6	Code of Conduct and International Dialogue	507
25.6	Conclusion	508
	References	508
26 Situation in Europe and the World: Societal Risks and Benefits of New Nanometric Products 511		
	<i>Jean-Marc Brignon</i>	511
26.1	Socio-Economic Assessment of Chemical Substances in Europe....	511
26.2	Does the REACH Regulation Apply to Nanometric Products?	512
26.3	Limitations of Cost–Benefit Analysis in the Case of Nanotechnology	513
26.4	Using the Results of Socio-Economic Analysis. The Precautionary Principle.....	515
26.5	Beyond Risk and Precaution	515
	References	516
27 Situation in Europe and the World: The European Nanotechnology Observatory		
	<i>M. Morrison</i>	519
27.1	The Role of the ObservatoryNANO Project	519
27.2	Approach Taken by the ObservatoryNANO	520
27.3	Interaction with Other Organizations	521
27.3.1	Organisation for Economic Co-operation and Development (OECD)	521
27.3.2	International Activities in Standards	522
27.3.3	European Technology Platforms (ETPs) and Joint Technology Initiatives (JTIs).....	522
27.3.4	Manufacturing Initiatives	522
27.4	Science and Technology Assessment	524
27.4.1	Publication Analysis	527
27.4.2	Patent Analysis	528
27.5	Economic Analysis	528

27.6	Integrating an Analysis of the Wider Aspects of Nanotechnology Development	534
27.6.1	Ethical and Societal Aspects	535
27.6.2	Environment, Health and Safety (EHS) Issues	535
27.6.3	Developments in Regulation and Standards	536
27.7	Supporting Research and Business	537
27.8	Establishing a Permanent European Observatory on Nanotechnologies	538
27.9	Conclusion and Future Work	538
27.10	About the Project Consortium	539
	References	539
28	Situation in Europe and the World: Nanotechnology and Scientific Policy. Action of UN Agencies in Developing Countries	541
	<i>Shamila Nair-Bedouelle</i>	541
28.1	Scientific Policy for Sustainable Development	541
28.2	Missions of Specialised UN Agencies	542
28.3	The Millennium Development Goals (MDGs)	543
28.3.1	Objectives	543
28.3.2	Current Status of MDGs	543
28.4	Nanotechnology and Politics	544
28.5	Other Political Considerations Regarding Nanotechnology: Patents	546
28.6	Needs of Developing Countries	547
28.7	The Future: Nanotechnology and Development	548
	References	548
29	Nanotechnology and the Law	551
	<i>Sonia Desmoulin-Canselier and Stéphanie Lacour</i>	551
29.1	The Law in the Face of Societal Concerns over Nano-Objects and Nanotechnology	552
29.1.1	How to Account for Uncertain, Even Fuzzy Risks	554
29.1.2	Taking into Account the Life Cycle of Nanoproducts	557
29.2	The Law in the Face of Nanotechnology Development Policies	559
29.2.1	The Territoriality of the Law in a Context of International Competition	560
29.2.2	The Specificity of the Law and Alternative Means of Regulation	563
	References	565

Part VI Nanoethics and Social Issues

30 How the Risks of Nanotechnology Are Perceived	573
<i>Daniel Boy and Solange Martin</i>	573
30.1 Criteria Giving Structure to Perception	573
30.2 Nanotechnology: A Checklist of Risk Perception	575
30.2.1 The Attitude Toward Nanotechnology in France	575
30.2.2 Attitudes Toward Nanotechnology in the European Union	577
30.2.3 European Experts and the Different Applications of Nanotechnology	580
30.3 What Should Be Done with Perceptions?	583
References	585
31 Robotics, Ethics, and Nanotechnology	587
<i>Jean-Gabriel Ganascia</i>	587
31.1 Preliminaries	587
31.2 Prehistory and History of Robot Ethics	588
31.3 Roboethics	590
31.3.1 A Roadmap for Roboethics	591
31.3.2 Ethics of Virtual Robots	593
31.3.3 Responsibility Toward Robots	595
31.4 Extrapolation to Nanoscience	596
31.4.1 Reality and Virtuality	596
31.4.2 Do We Need a Roadmap for Nanoethics?	597
31.4.3 Collision and Contamination Between Spheres of Intelligibility	598
References	599
32 Ethics and Industrial Production	601
<i>Daniel Bernard</i>	601
32.1 Some Observations	603
32.2 Strategy	606
32.3 Safety	607
32.4 Acquisition of Knowledge	609
32.5 Transparency	611
32.6 Conclusion	612
References	612
Index	613

List of Contributors

Wafa Achouak

Laboratoire d'écologie microbienne
de la rhizosphère (LEMIR)
UMR 6191 CNRS CEA Université
Aix Marseille II
CEA Cadarache
13108 Saint Paul lez Durance
wafa.achouak@cea.fr

Olivier Aguerre-Chariol

Innovation pour la mesure
Direction des risques chroniques
Institut national de l'environnement
industriel et des risques (INERIS)
Parc technologique ALATA
60550 Verneuil-en-Halatte
olivier.aguerre-chariol
@ineris.fr

Mélanie Auffan

Centre européen de recherche et
d'enseignements des géosciences de
l'environnement (CEREGE)
UMR 6635 CNRS Aix/Marseille
Université
Equipe SE3D
Europole de l'Arbois BP 80
13545 Aix-en-Provence Cedex 4
auffan@cerege.fr

Armelle Baeza-Squiban

Université Paris Diderot-Paris 7
Laboratoire des réponses
moléculaires et cellulaires aux
xénobiotiques (RMCX)
Unité de biologie fonctionnelle et
adaptative (BFA), EAC CNRS 4413
Case 7073
5 rue Thomas Mann
75205 Paris Cedex 13
baeza@univ-paris-diderot.fr

Denis Bard

Département d'épidémiologie
Ecole des hautes études en santé
publique
Avenue du Professeur Léon-Bernard
CS 74312
35043 Rennes Cedex
denis.bard@ehesp.fr

Laïla Benameur

Laboratoire de biogénotoxicologie et
mutagenèse environnementale
EA 1784, FR 3098 ECCOREV
Faculté de médecine
Université d'Aix-Marseille
27 Bd Jean-Moulin
13385 Marseille Cedex 05
laila.benameur@univmed.fr

Daniel Bernard

ARKEMA
420 Rue D'Estienne D'Orves
92705 Colombes
daniel.bernard@arkema.com

Daniel Bloch

Medical Advisor on Nanomaterials
Commissariat à l'énergie atomique
(CEA)
17 rue des Martyrs
38054 Grenoble Cedex 9
daniel.bloch@cea.fr

Frédéric Y. Bois

Technological University
of Compiègne (UTC)
Chair of Mathematical Modelling
for Systems Toxicology
Royallieu Research Center
BP 20529
60205 Compiègne Cedex
frederic.bois@ineris.fr

Jacques Bordé

Comité d'éthique des sciences du
CNRS (COMETS)
jacques.borde@polytechnique.
org

Alain Botta

CHU Timone
13385 Marseille Cedex 5
Laboratoire de biogénotoxicologie et
mutagenèse environnementale
EA 1784, FR 3098 ECCOREV
Faculté de médecine
Université d'Aix-Marseille
27 Bd Jean-Moulin
13385 Marseille Cedex 05
alain.botta@univmed.fr

Jean-Yves Bottero

Centre européen de recherche et
d'enseignements des géosciences de
l'environnement (CEREGE)

UMR 6635, CNRS/Université
d'Aix-Marseille
Europole de l'Arbois BP 80
13545 Aix-en-Provence Cedex 4
bottero@cerege.fr

Daniel Boy

Centre de recherches politiques de
Sciences Po
CEVIPOF
98, rue de l'Université
75007 Paris
daniel.boy@sciences-po.fr

Roberta Brayner

Nanomaterials Team
University of Paris 7 Paris-Diderot
Interfaces, traitements, organisa-
tion et dynamique des systèmes
(ITODYS)
CNRS UMR 7086
Bât. Lavoisier, 8ème étage, salle 820
15 rue Jean de Baïf
75205 Paris Cedex 13
roberta.brayner@univ-paris-
diderot.fr

Jean-Marc Brignon

Economics and Decision Tools
Chronic Risks Division
Institut national de l'environnement
industriel et des risques (INERIS)
Parc Technologique ALATA
60550 Verneuil-en-Halatte
jean-marc.brignon@ineris.fr

Patrick Brochard

Laboratoire santé, travail, environ-
nement (EA 3672)
Université Victor Segalen Bordeaux 2
146, rue Léo Saignat
Case 11
33076 Bordeaux Cedex
patrick.brochard@chu-
bordeaux.fr

José Cambou

Santé-Environnement de France
Nature Environnement
6 rue Dupanloup
45000 Orléans
jose.cambou@fne.asso.fr

Marie Carrière

Equipe toxicologie humaine et
environnementale
UMR 3299 CEA/CNRS, SIS2M
91191 Gif-sur-Yvette Cedex
carriere@drecam.cea.fr

Corinne Chanéac

Laboratoire de chimie de la matière
condensée
UMR 7574 UPMC/CNRS
Collège de France, Bât. C-D
11 place Marcelin Berthelot
75231 Paris Cedex 05
corinne.chaneac@upmc.fr

Sonia Desmoulin-Canselier

Centre de recherche Droit, Sciences
et techniques (CRDST)
Bureau 407
UMR 8103 CNRS/Université Paris 1
9, rue Malher
75004 Paris
Sonia.Desmoulin@univ-paris1.fr

François Ewald

Conservatoire national des arts et
métiers (CNAM)
Observatoire du principe de
précaution
2, rue Conté, 75003 Paris
francois.ewald@cnam.fr

Fernand Fievet

Laboratoire interfaces, traitements,
organisation et dynamique des
systèmes (ITODYs)
CNRS UMR 7086, Université Paris 7
Diderot

Bâtiment Lavoisier

15, rue Jean Antoine de Baïf
75205 Paris Cedex 13
fernand.fievet@univ-paris
-diderot.fr

Emmanuel Flahaut

Centre Interuniversitaire de
Recherche et d'Ingénierie des
Matériaux (CIRIMAT)
UMR CNRS 5085
University Paul Sabatier
Bâtiment 2R1
31062 Toulouse Cedex 9
NAUTILE (Nanotubes et
écotoxicologie)
ARKEMACNRS/UPS/INPT
flahaut@chimie.ups-tlse.fr

Eric Gaffet

Nanomaterials Research Group
(NRG)
CNRS UMR 5060
Site de Sévenans (UTBM)
90010 Belfort Cedex
eric.gaffet@utbm.fr

Philippe Galiay

European Commission
Directorate General for Research
SDME 7/68
B-1049 Brussels, Belgium
philippe.galiay@ec.europa.eu

Jean-Gabriel Ganascia

Laboratoire d'informatique de Paris
6 (LIP6)
Université Paris 6 Pierre and Marie
Curie
Boîte courrier 169
Couloir 25-26, Etage 5, Bureau 510
4 place Jussieu
75252 Paris Cedex 05
Jean-Gabriel.Ganascia@LIP6.fr

Jeanne Garric

CEMAGREF
Laboratory of Ecotoxicology
Freshwater systems, ecology
and pollution research unit
3 bis, quai Chauveau CP 220
69336 Lyon Cedex 09
jeanne.garric@cemagref.fr

Laury Gauthier

University of Toulouse III
Laboratoire d'écologie fonctionnelle
(Ecolab, UMR 5245)
CNRS/UPS/INPT
Avenue de l'Agrobiopole
BP 32607
Auzeville tolosane
31326 Castanet-Tolosan
NAUTILE (Nanotubes et
écotoxicologie), ARKEMA-
CNRS/UPS/INPT
lgauthie@cict.fr

Christine O. Hendren

Civil and Environmental Engineering
Department
Duke University
Hudson Hall Box 90287
Durham, North Carolina 27708, USA
christinehendren@gmail.com

Christian Huard

Association de défense, d'éducation
et d'information du consommateur
(Adéic)
3, rue de la Rochefoucauld
75009 Paris
christian.huard@adeic.asso.fr

Philippe Hubert

Risques chroniques
Institut national de l'environnement
industriel et des risques (INERIS)
Parc technologique ALATA
60550 Verneuil-en-Halatte
philippe.hubert@ineris.fr

Marie-Claude Jaurand

Institut national de la santé et de la
recherche médicale (INSERM U674)
27 rue Juliette Dodu
75010 Paris
marie-claude.jaurand@inserm.fr

Jean-Pierre Jolivet

Laboratoire de chimie de la matière
condensée
UMR 7574 UPMC/CNRS, Paris
Collège de France, Bât. C-D
11 place Marcelin Berthelot
75231 Paris Cedex 05
jean-pierre.jolivet@upmc.fr

Béatrice L'Azou

EA3672 Université Victor Segalen
Bordeaux 2
146, rue Léo Saignat
33076 Bordeaux Cedex
beatrice.lazou@u-bordeaux2.fr

Jérôme Labille

Centre européen de recherche et
d'enseignements des géosciences de
l'environnement (CEREGE)
UMR 6635 CNRS Aix/Marseille
Université
Europole de l'Arbois BP 80
13545 Aix-en-Provence Cedex 4
labille@cerege.fr

Stéphanie Lacour

Normativités et nouvelles
technologies
Centre d'études sur la coopération
juridique internationale (CECOJI)
UMR 6224 CNRS
Université de Poitiers
Faculté de Droit
Hôtel Aubaret
15, rue Sainte-Opportune
86022 Poitiers Cedex
lacour@ivry.cnrs.fr

Ghislaine Lacroix

Experimental Toxicology Unit
 Institut national de l'environnement
 industriel et des risques (INERIS)
 Parc technologique ALATA
 60550 Verneuil-en-Halatte
ghislaine.lacroix@ineris.fr

Sophie Lanone

Institut National de la Santé et de la
 Recherche Médicale (INSERM U955)
 Groupe Hospitalier Universitaire
 Albert Chenevier–Henri Mondor
 51, avenue du Maréchal-de-Lattre-
 de-Tassigny
 94010 Créteil Cedex
sophie.lanone@inserm.fr

Sophie Larrieu

Cellule de l'InVS en région (CIRE)
 Océan Indien
 2 bis, Av. G. Brassens
 97400 Saint Denis La Réunion
sophie.larrieu@ars.sante.fr

Olivier Le Bihan

Direction des risques chroniques,
 Institut national de l'environnement
 industriel et des risques (INERIS)
 Parc technologique ALATA
 60550 Verneuil-en-Halatte
olivier.le-bihan@ineris.fr

Agnès Lefranc

Institut de veille sanitaire (InVS)
 12 rue du Val d'Osne
 94415 Saint-Maurice Cedex
a.lefranc@invs.sante.fr

Corinne Mandin

Centre Scientifique et Technique du
 Bâtiment
 84 avenue Jean Jaurès

Champs-sur-Marne
 77447 Marne-la-Vallée Cedex 2
corinne.mandin@cstb.fr

Francelyne Marano

Université Paris Diderot-Paris 7
 Laboratoire des réponses
 moléculaires et cellulaires aux
 xénobiotiques (RMCX)
 Unité de biologie fonctionnelle et
 adaptative (BFA)
 CNRS EAC 4413 case 7073 Bâtiment
 Buffon
 4 rue Marie-Andrée Lagroua
 Weill-Hallé
 75205 Paris Cedex 13
marano@univ-paris-diderot.fr

Solange Martin

Sciences-Po, Paris
 27 rue Saint-Guillaume
 75337 Paris Cedex 07
 Agence de l'Environnement de la
 Maîtrise de l'Energie (ADEME)
 Paris
solange.martin@sciences-po.org

Armand Masion

Centre européen de recherche et
 d'enseignements des géosciences de
 l'environnement (CEREGE)
 UMR 6635 CNRS Aix/Marseille
 Université
 Europole de l'Arbois BP 80
 13545 Aix-en-Provence Cedex 4
masion@cerege.fr

Mark Morrison

Chief Executive Officer
 Institute of Nanotechnology
 Strathclyde University Incubator
 Graham Hills Building
 50 Richmond Street
 Glasgow G1 1XP
 Scotland
mark.morrison@nano.org.uk

Florence Mouchet

Laboratoire d'écologie fonctionnelle
(ECOLAB)
UMR 5245 CNRS/UPS/INPT

Laboratoire commun NAUTILE
(Nanotubes et Ecotoxicologie)
CNRS/UPS/ INPT, ARKEMA
florence.mouchet@orange.fr

Shamila Nair-Bedouelle

INSERM, Paris
snairbedouelle@gmail.com

Jean-Claude Pairon

Institut National de la Santé et de la
Recherche Médicale (INSERM U955)
Groupe Hospitalier Universitaire
Albert Chenevier-Henri Mondor
51, avenue du Maréchal-de-Lattre-
de-Tassigny
94010 Créteil Cedex
jc.pairon@chicreteil.fr

Corine Pelluchon

University of Poitiers,
Centre de recherche Hegel et
l'idéalisme allemand (CRHIA)
8 rue Descartes
86022 Poitiers Cedex
Centre de recherche sens, éthique et
société (CERSES)
University of Paris 5 René Descartes
45 rue des Saints-Pères
75006 Paris
corine.pelluchon@univ-
poitiers.fr

Alain Pompidou

Honorary Member of the European
Parliament
Former president of the European
Patents Office
President of the French National
Academy of Technologies
President of COMEST (UNESCO)
apompidou@skynet.be

Dominique Proy

Directoire du réseau Santé-
Environnement de France Nature
Environnement
6 rue Dupanloup
45000 Orléans
proydomi@yahoo.fr

Myriam Ricaud

Institut national de recherche et de
sécurité (INRS)
30 rue Olivier Noyer
75680 Paris Cedex 14
myriam.ricaud@inrs.fr

Jérôme Rose

Centre européen de recherche et
d'enseignements des géosciences de
l'environnement (CEREGE)
UMR 6635 CNRS Aix/Marseille
Université
Europole de l'Arbois BP 80
13545 Aix-en-Provence Cedex 4
rose@cerege.fr

Françoise Roure

Conseil général de l'industrie, de
l'énergie et des technologies
Ministère de l'Economie, de
l'Industrie et de l'Emploi
francoise.roure@finances.
gouv.fr

Antoine Thill

Laboratoire interdisciplinaire sur
l'organisation nanométrique et
supramoléculaire (LIONS)
(IRAMIS), UMR 3299 CEA/CNRS
CEA Saclay, Bâtiment 125
91191 Gif-sur-Yvette
antoine.thill@cea.fr

Eric Thybaud

Institut national de l'environnement
industriel et des risques (INERIS)
Parc technologique ALATA
60550 Verneuil-en-Halatte
eric.thybaud@ineris.fr

Bernard Umbrecht

Association de défense, d'éducation
et d'information du consommateur
(Adéic)
3, rue de la Rochefoucauld
75009 Paris
bernard.umbrecht@adeic.asso.fr

Mark R. Wiesner

Wiesner Research Group
Department of Civil and Environ-
mental Engineering
Duke University
Box 90287 Hudson Hall
Durham, North Carolina 27708

USA

Center for the Environmental
Implications of NanoTechnology
(CEINT)
wiesner@pratt.duke.edu

Olivier Witschger

Laboratoire de métrologie des
aérosols
Institut national de recherche et de
sécurité (INRS)
Rue du Morvan
CS 60027
54519 Vandoeuvre-lès-Nancy Cedex
olivier.witschger@inrs.fr

Introduction. Nanomaterials and Nanoproducts: World Markets and Human and Environmental Impacts

Eric Gaffet

Nanotechnology and nanoscience lie at the meeting point of many disciplines, from physics to chemistry, biology, and mechanics. Today they have become established as one of the main fields of research for the coming years. The first volume of this series, entitled *Nanoscience: Nanotechnologies and Nanophysics*, shows how useful it can be to structure matter on the nanoscale, with implications in fields as disparate as magnetism, data storage, biology, and electronics, with the development of completely new components, e.g., near-field techniques, lithographic processes, fullerenes, and spin electronics.

The second volume, *Nanomaterials and Nanochemistry*, presents a complete overview of nanomaterials, their fundamental properties, and novel applications that may come from fullerenes, carbon nanotubes, and other previously unimagined materials. This book provides a broad panorama of the main methods used to synthesise nanomaterials, and the resulting production processes, not forgetting the self-assembly of complex structures, one of the most promising channels of investigation opened up by nanochemistry.

The third book in the series, *Nanoscience: Nanobiotechnology and Nanobiology* provides an exhaustive and accessible overview of biological nano-objects, building blocks for existing and future constructions. After detailing the methods used for investigation in nanobiotechnology, there is a review of the many current and potential applications here, such as the synthesis of activatable nanoparticles able to accurately target cancer cells.

Coming directly from laboratory work in a highly accelerated way compared with other fields of research, the introduction and implementation of nanomaterials in nanoproducts has already become an industrial and economic reality. As in other industrial sectors, it is important to consider the social consequences (nanoethics) and the impact of these novel products on both human health and the environment (nanotoxicity), in order to avoid possible risks in the future. This is indeed a crucial issue to guarantee a responsible development of nanomaterials and nanotechnology, and it is the subject of the present volume.

1 Nanotechnologies

This field of research and development consists in building structures, devices, and systems using processes for structuring matter on the atomic, molecular, and supramolecular level, with characteristic length scales of 1–100 nanometres (nm). These so-called building blocks form a relatively small fraction of nanomaterials in terms of the quantity produced. In the field of nanomaterials, one must also consider nanoparticles and nanostructured coatings, but also dense bulk materials and nanocomposites (with organic, inorganic, or metallic matrices).

Matter is expected to behave in new ways, owing to the relative importance of the laws of quantum physics that find their full expression on this length scale. Many industrial and medical applications are currently being developed at a tremendous rate, and some have already been fully implemented.

For these reasons, one may consider the advent of the nanosciences (nanotechnology and nanomaterials) as a turning point in the industrial development of the twenty-first century.

2 Nanomaterials

A nanomaterial can be defined as a material made up of nano-objects, for which at least one of the three physical dimensions lies in the range 1–100 nm, and displaying specific nanoscale properties. These nano-objects may be particles, fibres, or tubes (one speaks of fillers and strengtheners), or structural constituents.

These nano-objects are used either as-is, e.g., catalysts for chemical reactions, vectors for carrying medicines to target cells, substances for polishing wafers and hard disks in microelectronics, etc., or for synthesising nanomaterials. The latter fall into three categories:

1. *Nanostrengthened Materials.* The nanoobjects are incorporated or produced in a matrix in order to ensure some new functionality or modify its physical properties. A good example is provided by nanocomposites, where these modifications improve resistance to wear.
2. *Surface-Nanostructured Materials.* Here the nano-objects are used to constitute a surface coating. Fabrication procedures for these coatings exploit techniques of physical deposition like physical vapour deposition (PVD), electron beams, laser ablation, and so on, or techniques of chemical deposition, like chemical vapour deposition (CVD), epitaxy, sol-gel, and so on.
3. *Bulk-Nanostructured Materials.* Nano-objects can also be constituents of bulk materials which, through features of their intrinsic nanometric structure, like porosity, microstructure, or nanocrystalline lattice, display specific physical properties.

3 Social and Economic Aspects

3.1 Nanotechnology and Nanomaterials Markets

The European Commission estimates that the world nanotechnology market was slightly above 40 billion euros in 2001. But by 2008, the global market for products resulting from nanotechnology was expected to reach more than 700 billion euros. In 2010–2015, the economic consequences of nanotechnologies should weigh in at around 1 000 billion euros per year, if all sectors are included, according to the US National Science Foundation, with some 340 billion euros of this specifically in the area of nanomaterials (Hitachi Research Institute). As a consequence, nanotechnological enterprises may directly employ 2 to 3 million people in the world.

3.2 Financing in France

The study [1] assessed public investment in the nanotechnologies. It shows that France is making a considerable effort in this direction. According to this study, taking into account the whole range of credits made available and the means allocated in this field by the French national research organisation (CNRS) and the French atomic energy authority (CEA), including staffing costs, the final figure is 551.6 million euros without including tax, or 637 million euros all included, for 2003. However, although it is sometimes possible to identify a specifically nanotechnological activity, such a distinction cannot always be made, and would generally have little meaning.

Quantitatively speaking, there is a very significant level of public funding in the field of nanotechnology and nanomaterials in France, both in absolute value and also in relation to France's main European partners, i.e., Germany and Great Britain. But this financing is well below the level in Japan and the United States.

In France, since 2005, calls for national programmes (ANR, A2I, etc.) have supported coordinated assessment of the effects nanoparticles may have on health. Eighteen months after the recommendations made by reports from the French agency for health and safety at work and in the environment (*Agence française de sécurité sanitaire de l'environnement et du travail* AFSSET) [2] and the French commission for prevention and safeguards (*Comité de la prévention et de la précaution* CPP) [3], which stress the need to coordinate ways of controlling risks on a national, if not European, level, a panel of experts was set up within the French public health authority (*Haut Conseil à la Santé Publique* HCSP), with the title *Groupe de veille sur les impacts sanitaires des nanotechnologies* (GVISN).

This interministerial watchdog is briefed to provide analyses and make recommendations with regard to relevant questions raised either within or outside the group, in order to provide the government (the Ministry of Health

and other ministries that may be concerned by this subject, such as environment, agriculture, research, and industry) with the support and advice it will need to define policy and handle new issues raised by nanomaterials and nanotechnology with regard to health and safety. At the beginning of 2009, on the basis of information provided by the GVISN, the HCSP made a pronouncement regarding carbon nanotubes [4].

At the end of 2005, all governments taken together had spent some 18 billion dollars to finance the nanotechnology and nanomaterials sector. With close to 6 billion dollars more in 2006, it was estimated that this world level of funding had equalled the whole of the Apollo programme which took men to the Moon.

3.3 Production and Applications of Nanomaterials

World Market

There are many applications of nanomaterials, as can be seen from Table 1 [5]. The world nanoparticle market for energy applications was estimated as around 54.5 million euros in 2000 and was expected to reach 77 million euros in 2005, i.e., a mean annual growth rate of 7%. This market has been driven by increasing awareness of the need to protect the environment. Nanoparticles are used for catalysis applications in the car industry, ceramic membranes, fuel cells, photocatalysis, propellants and explosives, antiscratch coatings, structural ceramics, and thermal spray coatings.

The world nanoparticle market for biomedical, pharmaceutical, and cosmetic applications [6] was estimated at 85 million euros in 2000 and was expected to reach 126 million euros in 2005, i.e., a mean annual growth rate of 8.3%. This is the market represented by the inorganic particles used to produce antibacterial agents, biological tags for research and diagnostics, biomagnetic separation processes, drug carriers, contrast media for magnetic resonance imaging (MRI), orthopedic devices, and solar protection screens.

The worldwide annual production of nanocomposites currently amounts to just a few thousand tonnes, mainly in cabling and packaging. However, by 2010, this production is expected to leap to 500 000 tonnes per year. Markets have been identified in the transport, engineering, and high technology sectors, due to the potential these materials have for strengthening structures while making them lighter, together with different design possibilities, e.g., reduction of thickness.

By 1995, the production of carbon black had already reach around 6 million tonnes per year worldwide. By 2005, global production was estimated at 10 million tonnes. The production of silica is around 300 000 tonnes per year, while titanium oxide has reached some 3.5 million tonnes for particles with micrometric dimensions, and close to 3 800 tonnes of nanoparticles were produced in 2000. The volume of aluminium nanoparticles is estimated at around 100 tonnes per year worldwide.

Table 1. Applications of different types of nanomaterial

Nanomaterial	Field of application
Nanoceramics	Structural composite materials Anti-UV components Mechanochemical polishing of wafers in microelectronics Photocatalysis applications
Nanometals	Antibacterial and or catalysis sectors Conducting films for screens, sensors, or energy generating materials
Nanoporous materials	Aerogels for thermal insulation in electronics, optics, and catalysis Biomedical applications to drug carriers and implants
Nanotubes	Electrically conducting nanocomposites Structural materials Single-sheet nanotubes for electronics and screens
Bulk nanomaterials	Hard coatings Structural components for the aeronautic industry, cars, ducts in the petroleum and gas industries, the sports sector, and anticorrosion applications
Dendrimers	Medical applications, including administration of medicines, fast detection techniques Cosmetics
Quantum dots	Optoelectronics (screens) Photovoltaic cells Inks and paints for anticounterfeit tagging
Fullerenes	Sports (nanocomposites) and cosmetics sectors
Nanowires	Applications in conducting layers of screens or solar cells and in electronic devices

French Production of Nanomaterials and Their Current Uses

According to a report published in 2007 by the French *Institut national de recherche et de sécurité* (INRS) [7], a first general survey of French nanoparticle production could already be drawn up. This information was consolidated in 2008 by elements from an AFSSET report entitled *Nanomaterials and Safety at Work* [2].

The main themes of the INRS report regarding the different nanoparticles produced in France can be summarised as follows:

- *Titanium Dioxide*. The French production of TiO_2 is around 240 000 tonnes. Different sizes of particle are used, depending on the sector, in the range 150–400 nm as pigment or opacifier in the paint and plastics industries, positioning them at the upper end of the nanoparticle range. The production of nanometric titanium dioxide is all carried out by 270

workers at one site, and reaches some 10 000 tonnes per year for three applications: architectonics, cosmetics, and air purification systems.

- *Silica*. With a production of 200 000 tonnes of SiO_2 , France is the second largest producer of natural silica in the world, extracting from one particular rock called diatomite. This production occurs at two extraction sites and involves about a hundred workers. As far as synthetic silica is concerned, i.e., precipitated silica, pyrogenic silica, and fumed silica, the annual production is greater than 100 000 tonnes and involves some 300 people. The main use is rubber reinforcement for tyres (where it is associated with carbon black in a 1:1 ratio), shoe soles, and rubber technical parts for wires and cables. In the food industry, these silicas are used as substrates for vitamins, acidifiers, and anticaking agents. The paint industry uses them as matting agents, while toothpaste manufacturers use them as thickeners and mild abrasives.
- *Nanoclays*. Two countries share the whole market here, Germany and the US. One site is currently under development for nanoclay production in France. A volume of around 100 tonnes is planned for 2007. About 50 people should be employed there.
- *Single-Wall Carbon Nanotubes (SWCNT)*. The production capacity for this category of nanotubes is between a few grams and a few tens of kilograms per day. At the present time, the maximal capacity is produced by an American company with 40 kg/day, using chemical vapour deposition (CVD) and a gaseous mixture of $\text{Fe}(\text{CO})_5$ and CO (the HiPCO process). French production of SWCNT is currently limited to university research laboratories. Several sites are equipped to produce quantities of around 10 g, either using a similar, low temperature process (CVD or catalytic CVD), or using a high temperature process (arc or plasma).
- *Multiwall Carbon Nanotubes (MWCNT)*. These have produced by one French company since 2006. This production unit, with a capacity of 10 tonnes per year, was a pilot project, involving about 10 people. Production there will be increased to several hundred tonnes per year by the end of the decade.
- *Carbon Black*. This is essentially composed of spheres with diameters in the range 10–500 nm, in aggregations of between ten and a few hundred particles. French production was 240 000 tonnes in 2005. It is carried out at four production sites, and involves a workforce of around 350 people. Seventy percent of carbon black is used by the tyre industry. The proportion, which may reach 30% of the weight of a tyre, is tending to fall, being replaced by precipitated silica. The rubber industry also uses it to make protective sheaths for cables and in the composition of conveyor belts, drive belts, and joints.
- *Aluminas*. A single production site in France produces ultrahigh purity aluminas. These are made using an alum process, i.e., aluminium sulfate with multihydrated ammonia. Two horizontal units are being set up at the site to take production to 1 000–1 700 tonnes per year from 2008. Other

producers share the alumina market. This so-called speciality alumina is synthesised by the Bayer process which uses bauxite as raw material. French production of speciality aluminas represented 468 000 tonnes in 2004. This includes a proportion of ultrafine and nanostructured alumina on top of the traditional range.

Future Developments and Markets

According to the investigation by Rocco in 2004 [8], there are four main stages in the development of nanotechnology and nanomaterial production: passive nanostructures, active nanostructures, systems of nanosystems, and molecular nanosystems. Currently commercialised nanoproducts belong mainly to the first category of passive nanostructures.

An active nanostructure is one that can modify its own state, e.g., morphology, shape, and mechanical, electronic, magnetic, optical, or biological properties, and so on, during its use. As an illustration, a mechanical actuator might change size, while the morphology and/or chemical composition of nanoparticles used as drug carriers in medicine might evolve in order to get through biological barriers, for example. These novel states of nanostructures might in turn evolve, in particular, to make them harmless at the end of their life cycle. Such changes will be all the more complex as the structures and systems are required to become more bulky and to implement several functions.

Examples of such active nanostructures are the nanoelectromechanical systems (NEMS), biological nanodevices, transistors, amplifiers, pharmaceutical and chemical carriers, molecular machines, light-activated molecular motors, nanofluidic systems, sensors, and radiofrequency identification devices (RFID).

In the field of tagging and identification, it should be stressed that some systems are already operational. As an illustration, in 2006, Hitachi presented the smallest RFID chip ever made. With dimensions $0.05 \times 0.05 \text{ mm}^2$, it has been referred to as smart dust. It contains a 128 bit read-only memory (ROM) that can stock a 38 digit identity number and it is easily integrated into a sheet of paper, for example. Recall that an RFID chip is used for automatic identification of whatever it tags. RFID chips can contain all kinds of information and are found on a great many different items, from passports to labels on products on sale at the supermarket, not to mention concert tickets. The advent of RFIDs in the form of a dust makes it easy to integrate them into ever more varied items. In parallel with these developments, a UK company has developed a device that can locate such RFID chips at up to a distance of 180 m [9] and to an accuracy of 2 cm in a 3D region. The possibility of such a high degree of miniaturisation has raised questions about tracking and checking up on individuals without them knowing.

In medicine, nanomaterials are already used in commercialised medical equipment, such as bandages, implants, prosthetics, and others. Medical

biology uses nanoelements for in vitro diagnosis of infectious diseases, immunological disorders, and cancers. Some devices for day-to-day medical observation of biological parameters, e.g., glycaemia, will usefully benefit from the extreme miniaturisation made possible by nanotechnology. The medical imaging sector is also investigating the possibilities for improving the contrast and resolution of MRI images by placing nanoparticles in target organs. Pharmacological research has long been exploring the possibility of carrying therapeutic drugs as close as possible to lesions, using nanoparticles designed to target sick cells. Therapeutic trials are under way, especially in the field of cancer treatment. Nanotechnologies may one day be able to customise drugs. Some nanoparticle contrast agents and drugs have already been accepted by the relevant regulatory bodies.

One application in particular has seen rapid development and no doubt benefits significantly from progress in miniaturisation as procured by nanotechnology, and that is deep brain stimulation by microelectrodes placed in the brain [10]. Since the 1980s, a team in Grenoble (France) led by Professor A.L. Benabid has discovered that electrical stimulation of a certain part of the brain can reduce or completely remove the shaking symptoms of those suffering from Parkinson's disease. Since then, in collaboration with several international teams, applications to other medical problems have been proposed, including acute dystonia (a neurological movement disorder), epilepsy, and others. The technique was then tested – with the agreement of the French *Comité consultatif national d'éthique pour les sciences de la vie* (CCNE)¹ – in the treatment of obsessive-compulsive disorders (OCD) and depressive syndromes that could not be relieved by conventional medical treatments. At the present time, some 35 000 people are being treated by this 'brain pacemaker', including about 1 000 in France. Other research is investigating the brain-machine interface, with a view to controlling muscular movements either by acting directly on the nerve or muscle fibres, or by going through the central nervous system. These are promising applications for people suffering from paralysis or anomalous movements (tics).

However, these techniques carry the risk of side-effects, in particular when the electrode is implanted, since it may be rejected or cause brain hemorrhage. This is why the idea of using nanoscale electrodes came into being. In France, the CLINATEC project is a biomedical research center devoted to nanomedicine, focussing primarily on implanted devices and the brain-machine interface. It is important to debate the possible abuses of nanotechnology in medical applications, in particular for specific medical applications like deep brain stimulation.

It should also be stressed that there is a very clear dual development of nanotechnology and nanomaterials for specific defence applications. For example, items for personal protection such as bullet-proof vests and helmets incorporating carbon nanotubes, ultrafast and ultrasensitive detection devices,

¹ National Consultative Committee for the Life Sciences.

chemical and bacteriological carriers, exoskeletons (powered mobile frameworks worn by the soldier and interfaced on the human brain, which should make it possible to carry 80 kg for 80 km at more than 50 km/h, developed by DARPA, USA), not to mention the development of thermobaric bombs which use pyrophoric nanoparticles and produce equivalent blast waves to a nuclear weapon [11] – the first tests were carried out by the United States and Russia in 2007. This all-pervading dual aspect of nanotechnological applications raises the question of whether we should renew international negotiations about the proliferation of weapons of mass destruction with a view to drawing up new treaties.

3.4 Nanomaterials and Safety

Our current understanding of the effects of micro- and nanoparticles in atmospheric pollution has raised fears regarding the consequences of man-made nanoparticles for human health. While very few reliable data are available in this field, studies published about the interactions of nanoparticles at the cellular level suggest that we should be cautious. Recently, work by Donaldson et al. [4] tends to show that some carbon nanotubes can induce similar effects to asbestos fibres, inducing mesothelioma.

As shown as early as 2005 in a summary note [12], the important scientific questions regarding nanoparticles and health must be concerned with the whole life cycle and must consider the following specific features:

- The physicochemical characterisation and classification of nanoparticles according to their level of surface reactivity, a good indicator of potential biological effects.
- The detection and characterisation of exposure to these particles by everyone from factory employees to users.
- Their potential biological effects on humans.

These issues concern workers in the nanotechnology and nanomaterials sectors, who may be exposed to high concentrations of nanoparticles, but also the population at large, whose exposure to these nanoparticles is less direct and related to the life cycle of the nano-object in question.

Finally, the risks associated with nanoparticle explosions must also be given due attention. At the present time, little has been done, e.g., with regard to staff involved in the production of nanomaterials from such nanoparticles.

Given the importance of these issues, some websites have been set up to monitor publications in this area:

- *The Virtual Journal of Nanotechnology Environment, Health and Safety* [13].
- *Nanotechnology: Health and Environmental Implications – An Inventory of Current Research* [14].
- *Safe Production and Use of Nanomaterials* [15].

4 The Need for Studies in Nanotoxicity and Nanoethics

As discussed by Roure [16], the highly diverse industrial economy of nanotechnology and nanomaterials is well under way. Given the speed with which laboratory research is transformed into nanoproducts, some already commercialised, and given their all-pervading tendencies [17], the time has come to assess our current understanding of nanotoxicity, and also to address the relevant ethical questions. Indeed, research in nanoscience and nanotechnology stands out by the difficulty in distinguishing the fundamental from the technological. Synergies arise through the NBIC convergence (nanotechnology, biotechnology, information technology, and cognitive science) and their effects are difficult to quantify in the mid to long term. This fourth volume of the *Nanoscience* series aims to present the state of the art, both in the field of nanotoxicity and with regard to what we shall define as nanoethics. We hope it will contribute to a responsible and safe use of nanomaterials and nanotechnology.

References

1. *Le financement des nanotechnologies et des nanosciences. L'effort des pouvoirs publics en France: comparaisons internationales*, published in January 2004 on behalf of the French *Ministère de la Jeunesse, de l'Education nationale, et de la Recherche* (MJENR)
2. *Agence française pour la sécurité sanitaire de l'environnement et du travail* (AFSSET): Report on *Nanomatériaux: effets sur la santé de l'homme et sur l'environnement*, www.afsset.fr/?pageid=&newsid=105&MDLCODE=news&search=yes&txtSearch=nano; *Nanomatériaux et sécurité au travail*, www.afsset.fr/upload/bibliotheque/258113599692706655310496991596/afsset-nanomateriaux-2-avis-rapport-annexes-vdef.pdf
3. Conclusions of the *Comité de la prévention et de la précaution* (CPP): *Nanotechnologies, nanoparticules: quels dangers? quels risques?*, www.ecologie.gouv.fr/Avis-du-Comite-de-la-Prevention-et.html
4. Conclusions of the *Haut Conseil de la Santé Publique* (January 2009), www.hcsp.fr/hcspi/docspdf/avisrapports/hcspa20090107_ExpNanoCarbone.pdf
5. Report *Etude prospective sur les nanomatériaux*, on behalf of DIGITIP/MineFi by the French company *Développement & Conseil* (2004)
6. Report produced by the *Direction générale de l'industrie, des technologies de l'information et des postes* (2004)
7. B. Honnert, R. Vincent: Production et utilisation industrielle des particules nanostructurées. *Hygiène et Sécurité du Travail*, ND 2277 (2007)
8. M.C. Rocco: Nanoscale science and engineering: Unifying and transforming tools. *AICChE Journal* **50**, 890–897 (2004)
9. www.tfot.info/pod/152/rfid-loc8tor.html
10. NanoForum – Nanomedicine session (5 June 2008)
11. news.bbc.co.uk/2/hi/europe/6990815.stm

12. J. Boczkowski, E. Gaffet, A. Lombard: Note de synthèse pour le PNSE – Les déterminants environnementaux: nanoparticules et santé (2005)
13. The Virtual Journal of Nanotechnology Environment, Health and Safety, www.icon.rice.edu/virtualjournal.cfm
14. Nanotechnology: Health and Environmental Implications – An inventory of current research, www.nanotechproject.org/18/esh
15. Safe Production and Use of Nanomaterials: www.nanosafe.org
16. F. Roure: Economie internationale des nanotechnologies et initiatives politiques. *Annales des Mines*, 5–12 (2004)
17. Report by the *Office parlementaire des choix scientifiques et technologiques*. *Audition publique sur les nanotechnologies: risques potentiels, enjeux éthiques*. France (2006), no. Assemblée Nationale 3658, no. Sénat 208